Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 4/20 | 0.51 |
| ▸ | FNTB | P49356 | 4/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051670 | 1.00 | LMNA (0.51) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL1158062 | 1.00 | LMNA (0.51) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL30052673 | 0.94 | FNTA (0.50) | LMNAFNTAFNTBPGGT1BCA2 | |
| Trifluoroacetic Acid SCHEMBL8763021 | 0.91 | SMN1; SMN2 (0.47) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL11662923 | 0.89 | FNTA (0.49) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL11662915 | 0.89 | FNTA (0.49) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL30440147 | 0.88 | FNTA (0.55) | FNTAFNTBPGGT1B | |
| SCHEMBL30051202 | 0.88 | FNTA (0.45) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL7987401 | 0.88 | FNTA (0.48) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL7987408 | 0.88 | FNTA (0.48) | LMNAFNTAFNTBPGGT1BCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534510-B2 | Peptide-receptive MHC-I complex compositions and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-27 | — | — | US | claimed |
| EP-3817757-B1 | PEPTIDE DEFICIENT-MHC CLASS I/CHAPERONE COMPOSITIONS AND METHODS | UNIV CALIFORNIA (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4136098-B1 | PEPTIDE-RECEPTIVE MHC-I COMPLEX COMPOSITIONS AND METHODS FOR THEIR GENERATION | UNIV CALIFORNIA (US) | 2025-12-17 | — | — | EP | claimed |
| US-20240307428-A1 | SYNERGISTIC COMPOSITION FOR MAINTENANCE OF HEALTHY BALANCE OF MICROFLORA | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2024-09-19 | — | — | US | claimed |
| US-20240294601-A1 | PEPTIDE DEFICIENT-MHC CLASS I/CHAPERONE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF CALIFORNA | 2024-09-05 | — | — | US | claimed |
| US-12029748-B2 | Synergistic composition for maintenance of healthy balance of microflora | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2024-07-09 | — | — | US | claimed |
| US-11814420-B2 | Peptide deficient-MHC class I/chaperone compositions and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-14 | — | — | US | claimed |
| CN-115776987-A | Barcoded exchangeable peptide-MHC multimer libraries | 瑞佩尔托利免疫医药股份有限公司 | 2023-03-10 | — | — | CN | claimed |
| EP-4136098-A1 | PEPTIDE-RECEPTIVE MHC-I COMPLEX COMPOSITIONS AND METHODS | The Regents of the University of California (US) | 2023-02-22 | — | — | EP | claimed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | claimed |
| US-6472201-B1 | GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2002-10-29 | — | — | US | claimed |
| JP-2000508335-A | — | — | 2000-07-04 | — | — | JP | claimed |
| EP-0934270-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1997045412-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-12-04 | — | — | WO | claimed |
| EP-0783517-A2 | THIOL-FREE INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | claimed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | claimed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | claimed |
| US-4095000-A | AMINO ACIDS AND DERIVATIVES, POLYHYDROXY COMPOUNDS, NUTRIENTS, HYDROLYSIS | Brenner, Max (CH) | 1978-06-13 | — | — | US | claimed |
| US-3959519-A | Fortification of food materials with a methionine source | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | LMNA 3184/4885FNTA 776/4885FNTB 452/4885 |
| US-12534510-B2 | Peptide-receptive MHC-I complex compositions and methods | MICA, TAP2, TAP1 | LMNA 3263/4885FNTA 2320/4885FNTB 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.